Gentherm (NASDAQ: THRM) announced on July 20, 2026 that the U.S. Food and Drug Administration has granted 510(k) clearance to its patented ThermAffyx Patient Safety System — a Class II device that combines active underbody warming, anti-slip securement and pressure reduction in a single pad designed for the more than three million robotic-assisted surgical procedures performed globally each year.
The Problem It Solves
Surgical teams historically piece together separate warming blankets and securement straps. That is especially problematic in robotic procedures conducted in the steep head-down Trendelenburg position: studies show only 17-21% of the patient's body surface area is available for forced-air warming, and more than one in four robotic-surgery patients remain hypothermic in recovery despite warming interventions.
How ThermAffyx Works
ThermAffyx integrates a radiolucent heating element powered by Gentherm's proprietary Carbotex carbon-fiber technology directly into the anti-slip securement pad — so a single platform handles temperature, positioning and pressure management inside existing robotic surgical workflows.
Commercial Timeline
Product trials at healthcare facilities are scheduled to begin in August, with revenue generation expected to commence in Q3 2026. The clearance materially expands Gentherm's patient temperature management portfolio and pushes the company deeper into the ecosystem around Intuitive Surgical's da Vinci, Medtronic's Hugo and other robotic platforms. Gentherm booked roughly $1.5 billion in annual sales in 2025 and $2.2 billion in automotive new business wins; its medical business is a smaller but growing segment.
A Busy Week For Surgical Robotics
The clearance lands the same week Microbot Medical announced participation at the Society of Robotic Surgery annual meeting, less than a year after FDA clearance of its LIBERTY endovascular robotic system.
Reporting based on coverage from Gentherm, GlobeNewswire and StockTitan.